Episode
BioMarin's Q1: Mixed Results, Upgraded Guidance
- Published
- May 14, 2026
- Duration seconds
- 108
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/biomarin-s-q1-mixed-results-upgraded-guidance/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/biomarin-s-q1-mixed-results-upgraded-guidance.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
BioMarin Pharmaceuticals Q1 earnings missed expectations with revenue at $766.2M, up 2.8% YoY but short of $776M forecast, and adjusted EPS at $0.76, missing $0.91 estimate due to manufacturing issues and Amicus acquisition costs. Margins dropped to 16.9% from 30% last year. The company raised full-year revenue guidance to $3.88B, up 14.8% from before, but trimmed adjusted EPS to $4.95. Theyre focusing on Amicus integration, new drugs, and clinical data for upcoming products. Margin recovery and regulatory moves could drive stock momentum. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: [email protected] This is an automated, high-level news summary based on public reporting. Report issues to [email protected]. View sources & latest updates: https://sources.thednn.ai/ad7d7e64420f3557